Background Most women with newly diagnosed advanced ovarian cancer have a relapse
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …

INTRODUCTION: Patients diagnosed with epithelial ovarian cancer (EOC) have improved
outcomes when cared for at centers experienced in the management of EOC. The objective …

Background Data are limited regarding the use of poly (adenosine diphosphate [ADP]–
ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed …

OBJECTIVES.: The CA125 tumor marker is used to help predict the presence of ovarian
cancer in patients with an adnexal mass. Because elevated CA125 levels occur in many …

Importance Germline mutations inBRCA1andBRCA2are relatively common in women with
ovarian, fallopian tube, and peritoneal carcinoma (OC) causing a greatly increased lifetime …

Background Platinum-based chemotherapy doublets are a standard of care for women with
ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed …

Background There is a high unmet need for treatment regimens that increase the chance of
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …

Background A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of
drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel …

Background Late-line treatment options for patients with ovarian cancer are few, with the
proportion of patients achieving an overall response typically less than 10%, and median …

PURPOSE Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment
of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic …